Real-world Drug Survival of Guselkumab in Patients With Psoriasis Stratified by Weight and Comorbidities: Retrospective, Observational Data From the British Association of Dermatologists Biologics and Immunomodulators Register.

Savage L, Gkini MA, Wang X, Topping L, Chauhan B

Open source

DOI
10.1093/ced/llag363
Published
2026 Sep 8
Container
Clinical and experimental dermatology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/ced/llag363,
  title = {Real-world Drug Survival of Guselkumab in Patients With Psoriasis Stratified by Weight and Comorbidities: Retrospective, Observational Data From the British Association of Dermatologists Biologics and Immunomodulators Register.},
  author = {Savage L and Gkini MA and Wang X and Topping L and Chauhan B},
  year = {2026},
  journal = {Clinical and experimental dermatology},
  doi = {10.1093/ced/llag363},
  url = {https://doi.org/10.1093/ced/llag363}
}

RIS

TY  - JOUR
TI  - Real-world Drug Survival of Guselkumab in Patients With Psoriasis Stratified by Weight and Comorbidities: Retrospective, Observational Data From the British Association of Dermatologists Biologics and Immunomodulators Register.
AU  - Savage L
AU  - Gkini MA
AU  - Wang X
AU  - Topping L
AU  - Chauhan B
PY  - 2026
JO  - Clinical and experimental dermatology
DO  - 10.1093/ced/llag363
UR  - https://doi.org/10.1093/ced/llag363
ER  - 

APA

L, S., MA, G., X, W., L, T., & B, C. (2026). Real-world Drug Survival of Guselkumab in Patients With Psoriasis Stratified by Weight and Comorbidities: Retrospective, Observational Data From the British Association of Dermatologists Biologics and Immunomodulators Register.. Clinical and experimental dermatology. https://doi.org/10.1093/ced/llag363

Source records